KeborMed delivers the industry’s most advanced, regulatory compliant connectivity platform for MedTech and Pharma applications. Our plug-n-play solution transforms data management, bypassing traditional custom development hurdles. This empowers businesses to expedite high-quality drug discovery and delivery, significantly enhancing patient care and providing a competitive edge in the rapidly evolving healthcare landscape. To learn more, please visit https://kebormed.com/

Kaléo is dedicated to creating innovative healthcare solutions that help protect and empower patients. Our auto-injection technologies are protected by an extensive intellectual property portfolio of patents and meet the FDA draft guidance standard for 99.999% device reliability. Kaléo is privately-held and headquartered in Richmond, VA. Visit www.kaleo.com

Recipharm offers highly innovative design, development and manufacturing capabilities for injectable drug delivery devices to the global pharmaceutical market, offering a range of auto-injectors with our proprietary VapourSoft® technology. Keeping the end-user in mind, we produce auto-injectors designed to facilitate patient-friendly administration and overcome formulation challenges, particularly for high viscosity formulations. To learn more please visit: https://www.recipharm.com/

Secant Group’s innovative and patent-protected Hydralese® polymer platform provides an elastomeric and bioresorbable polymer that enables long-acting drug delivery. Secant’s material experts specialize in developing custom finished dosage forms for the delivery of a  variety of API’s. We have the expertise to support pharmaceutical payload delivery development to enable novel, patient-centric therapies that positively impact health. Learn more at secant.com/drug-delivery

We are a Canadian contract development and manufacturing organization (CDMO) specializing in the production of nucleic acid and lipid products that support life-enabling work. We strive towards this daily by developing and deploying our state-of-the-art bioprocessing and chemical process technologies, using proprietary manufacturing and analytical approaches, employing a highly skilled workforce, and partnering with an excellent and extensive network of relationships and collaborations. We support our customers by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field. We are dedicated to supporting our customers by providing scalable manufacturing capacity and accelerating innovation in bringing their products from the benchtop to real-world applications.

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS LOHMANN Therapie-Systeme AG. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) as well as wearable drug delivery devices (“OBDS”). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS’s innovation pipeline contains both partner-funded and proprietary, LTS-funded projects. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. To learn more, please visit www.ltslohmann.com

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity. For more information, visit: https://www.nanitebio.com/

Lifecore Biomedical is an integrated CDMO with expertise in specialty formulation, aseptic filling, and final packaging of complex medical devices and injectable pharmaceuticals. Capabilities include: FDA-approved commercial products, highly viscous products (in excess of 100,000 cP), process development, clinical and commercial manufacturing, on-site analytical services, and pharmaceutical-grade sodium hyaluronate production. To learn more, please visit https://www.lifecore.com/

Elligo Health Research accelerates clinical trials through EHR data, our proprietary IntElligo® technology, and direct access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. Our PatientSelect® model engages our network of networks to optimize the intersection of healthcare and research and bring more patients clinical research as a care option. Our SiteSelect model and Research Partner Services enable sites to seamlessly participate in trials, further advancing the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. For more information, go to https://www.elligohealthresearch.com/.

Merxin Ltd: We Make Inhalers. We make dry powder inhalers (DPI) and soft mist inhalers (SMI). Our range of soft mist, dry powder and multidose dry powder inhalers are ready to launch your molecules. Our capsule DPI MRX003 is on the market; our SMI MRX004 is the preferred option for both biologics and ultra-low carbon footprint; MRX006 is a multidose “open-inhaler-close” DPI; MRX002 is a see through cannister for HFA/HFO pMDI formulations. We Will Launch You. For more information, please visit www.MERXIN.com. 

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford, with the Head Office located in Woodstock, UK. Our global presence spans from manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany and France. Owen Mumford Pharmaceutical Services specializes in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech and generics industries. Our trusted devices are used daily in the delivery of various medications for a multitude of conditions across the globe. Our product portfolio includes single and multi-dose reusable and disposable auto-injectors, pens, and syringes for subcutaneous and intramuscular administration. Our flagship products include UniSafe® platform, a spring-free, passive safety device for 1ml and 2.25ml pre-filled syringes. UniSafe 1mL has regulatory approval as a combination product in Asia and Europe where it is also in patient use. Our most recent innovation is the 2-step disposable auto-injector Aidaptus®. Aidaptus can be used for both 1mL and 2.25mL syringes in the same base device. It can also readily adapt to different fill volumes using auto-adjust plunger technology providing a solution for formulation changes during development and lifecycle management. We are proud to have been awarded a distinction in the prestigious Red Dot awards for innovative product design 2023 for Aidaptus. For more information, visit https://www.ompharmaservices.com/

Reverba (formerly Health Perspectives Group) is a health engagement company that transforms the way healthcare companies think and function, making compliant, patient-centered action possible. Reverba signifies a multiplying force for amplifying the perspectives of patients and the impact of their voices. The word is also rooted in science: REV-ErbA is an essential protein that supports the circadian rhythms of life. Working with more than 30 biopharmaceutical companies over our storied history, we have built lasting relationships with thousands of patients directly, and our programs have reached millions of other patients indirectly as well. For more information, go to www.reverba.com